(Octadecanoylamino)propanedioic acid | 651312-94-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (Octadecanoylamino)propanedioic acid
• 英文别名: 2-(octadecanoylamino)propanedioic acid
• CAS: 651312-94-6
• 化学式: C₂₁H₃₉NO₅
• 分子量: 385.5
• InChiKey: ZMOIQOIFMKBZER-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.3
• 重原子数：
  27
• 可旋转键数：
  19
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  104
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• Ophthalmic solution of bimatoprost
  申请人：SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED

  公开号：US11241443B2

  公开（公告）日：2022-02-08

  The present invention relates to an ophthalmic solution comprising (i) bimatoprost or its pharmaceutically acceptable salt in an amount ranging from about 0.005% to 0.015% weight by volume; (ii) a biguanide compound in an amount ranging from about 0.003% to 0.05% weight by volume; (iii) an acylated amino acid in an amount ranging from about 0.01% to 0.1% weight by volume; (iv) pharmaceutically acceptable excipients and (v) purified water.

  本发明涉及一种眼科溶液，其中包括 (i) 比马前列素或其药学上可接受的盐，其用量按体积重量计约为 0.005%至 0.015%； (ii) 一种双胍化合物，其用量按体积重量计约为 0.003%至 0.05%； (iii) 一种酰化氨基酸，其用量按体积计约为 0.01%至 0.1%； (iv) 药学上可接受的赋形剂和 (v) 纯净水。
• [EN] OPHTHALMIC SOLUTION OF BIMATOPROST<br/>[FR] SOLUTION OPHTALMIQUE DE BIMATOPROST
  申请人：SUN PHARMA ADVANCED RES CO LTD

  公开号：WO2018185788A1

  公开（公告）日：2018-10-11

  The present invention relates to an ophthalmic solution comprising (i) bimatoprost or its pharmaceutically acceptable salt in an amount ranging from about 0.005 % to 0.015 % weight by volume; (ii) a biguanide compound in an amount ranging from about 0.003 % to 0.05 % weight by volume; (iii) an acylated amino acid in an amount ranging from about 0.01 % to 0.1 % weight by volume; (iv) pharmaceutically acceptable excipients and (v) purified water.
• [EN] DIFLUPREDNATE FOR REDUCING THE ADVERSE EFFECTS OF OCULAR INFLAMMATION<br/>[FR] DIFLUPREDNATE SERVANT À RÉDUIRE LES EFFETS INDÉSIRABLES DE L'INFLAMMATION OCULAIRE
  申请人：[en]SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED

  公开号：WO2022118271A1

  公开（公告）日：2022-06-09

  The present invention provides an aqueous solution comprising difluprednate as the sole active ingredient, wherein the aqueous solution comprises 0.02% to 0.04% w/v difluprednate and an aqueous vehicle, wherein the aqueous solution is free of oil and wherein the aqueous solution is administered twice-a-day for 7 to 21 days to the subject and a method of reducing an adverse effect associated with an inflammatory disorder of eye in a subject in need thereof, using said aqueous solution.